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Guest Editorial 
Assessment of animal pain and mechanism-based strategies for its reversal. 
Sue Fleetwood-Walker*, Liting Sun, Helen Jerina, Rory Mitchell 
Centre for Integrative Physiology, School of Biomedical Sciences, College of Medicine & 
Veterinary Medicine, University of Edinburgh, Hugh Robson Building, Edinburgh, EH8 9XD, 
UK. 
*Corresponding author. Tel.: +44 131 651 1696
E-mail address: s.m.fleetwood-walker@ed.ac.uk (S.M.Fleetwood-Walker). 
More effective relief is required for chronic inflammatory or neuropathic pain in 
animals as many of the conventional analgesics have significant side effects. A 
timely review by Roy Meintjes (page …, this edition) helps to highlight this need by 
overviewing the pathways and mechanisms for processing pain in the nervous 
system – likely targets for analgesics of the future.  
Progress in several areas is necessary to better define, treat and manage 
pain states thereby improving welfare in animals. These include: 1) accurate pain 
assessment using sensitive, reliable and refined methodology, 2) scientific 
understanding of the mechanisms of pain and novel targets for analgesia, 3) 
translational research for new treatments.  
For effective pain management, the first key requirement is pain assessment 
by approaches that avoid subjective inferences. Repeatable and accurate 
assessments of animals using quantitative sensory testing (QST), forms a means by 
which the hypersensitivity likely to reflect chronic pain may be quantified. Such 
measures are especially useful for assessing those animals that might benefit from 
improved analgesic treatments. The tests involved have generally been adapted 
from those for clinical pain measurements in human patients. They are easy to use, 
assess readily recognisable withdrawal responses and involve brief stimuli just below 
or at threshold noxious levels in unrestrained animals. A systematic approach is 
important to assess the different components of pain. Horses with chronic laminitis 
can show changes in sensory nerves innervating the forelimbs (Jones et al., 2007) 
revealing that nerve damage as well as inflammation is present. Laminitic horses 
correspondingly show increased levels of sensitivity in response to deformation of 
the hoof wall, using a calibrated, computerised, mechanical pressure device 
(Vinuela-Fernandez et al., 2011). Such assessment helps monitor the diseases’ 
progression and indicate that these animals suffer painful hypersensitivity to normally 
innocuous stimuli.  
Similarly assessments of altered weight bearing and sensitivity to cutaneous stimuli 
in dogs with osteoarthritis have identified accentuated responsiveness to mechanical 
(using von Frey filaments) and cold temperatures in the affected limb (Brydges et al., 
2012). These quantitative assessments form a necessary foundation for evidence 
based evaluation of whether an analgesic treatment is truly effective or not.   
Secondly, an appreciation of the changes that occur in the peripheral and central 
nervous system during chronic pain is of considerable benefit when trying to deliver 
effective analgesia. Key transducers in peripheral sensory neurons can show 
alterations following different kinds of injury. The transient potential channel, TRPA1 
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is the leading candidate mediator of such cold-sensitive responsiveness (Kwan et al., 
2006) and is notably facilitated by inflammatory mediators such as prostaglandins, 
bradykinin and inflammatory proteases (for example, (Bandell et al., 2004). Rapidly 
accumulating evidence is pointing towards TRPA1 as being an important mediator of 
mechanical hypersensitivity in chronic pain models (Kwan et al., 2009). Cold- and 
pressure-sensitive mediators in joint afferents contributing to hypersensitivity may 
include TRPA1 (McGaraughty et al., 2010). Changes in responsiveness to warm as 
well as to cold thermal stimuli in inflammatory conditions suggest that other 
mediators such as TRPV1 may also play a role and correspondingly, expression of 
TRPV1 is upregulated in osteoarthritis and following sensory nerve damage (Facer 
et al., 2007; Fernihough et al., 2005). Such channels may represent targets for future 
analgesics that can effectively treat pain hypersensitivity in a clinical setting.  
Further, as Roy Meintjes describes, there are also a number of important 
changes in the initial relays within the spinal dorsal horn that contribute to 
hyperexcitability. The increased spinal excitability can be transmitted to higher 
regions of the brain, thereby leading to accentuated perception of pain. At the spinal 
level, excitatory amino acid receptors, such as the NMDA receptor, linking with 
intracellular adapter molecules eg postsynaptic density-95 (PSD-95), can interact 
with signalling molecules to enhance processing and are important for sensitisation 
(Arbuckle et al., 2010; Garry et al., 2004). Enhanced transmission through the pain 
pathways at the level of the spinal dorsal horn will result. The AMPA receptor is also 
important in this process, as it is thought to be trafficked into synapses together with 
metabotropic glutamate receptors (mGluR) during chronic pain states (Garry and 
Fleetwood-Walker, 2004; Young et al., 1998). In the central nervous system longer 
term changes are highly likely following sensory afferent activation if the injury 
remains unresolved for a prolonged period of time. In early disease states or after 
surgical injuries, pre-emptive treatment may provide an opportunity to reduce these 
types of sensitisation events in the nociceptive processing pathways. Administration 
around the time of the initial injury, of an NMDA receptor antagonist, eg memantine 
or ketamine, appears to be more effective in preventing sensitisation than 
retrospective intervention (Wilson et al., 2005).  
One mechanistic issue to consider in chronic pain is that changes occurring in 
gene expression within sensory neurons may diminish the effectiveness of 
conventional analgesics. Neuropathic pain for example is notably resistant to many 
analgesics such as opioids. One reason may be that different neurotransmitters such 
as the neuropeptide vasoactive intestinal polypeptide (VIP) become expressed in 
injured primary sensory neurons, while their receptors such as the VPAC2 receptor 
show increased expression in spinal cord neurons (Dickinson and Fleetwood-
Walker, 1999). Such injury-specific events may represent refined targets for the 
design of novel analgesics. 
Finally it is important to consider that not only laboratory-based investigations 
but also the experience gained from their translation into human clinical medicine 
can give insights into new ways of treating animal pain. For example it was only 
recently established that activation of the TRPM8 ion channel in a subpopulation of 
primary sensory neurons reflects a novel and highly effective endogenous 
mechanism for chronic pain relief (Fleetwood-Walker et al., 2007; Proudfoot et al., 
2006). This can be achieved by topical application of selective TRPM8 activators 
such as menthol and is effective for both inflammatory or nerve damage situations. 
Topical administration of TRPM8 activators may form the basis of a new treatment 
strategy for chronic pain in both man and in animals. Early trials in human clinical 
settings are already providing promising evidence in support of its efficacy (Colvin et 
al., 2008; Storey et al., 2010).  
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